These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 6802504)

  • 21. Thymopoietin pentapeptide treatment of primary immunodeficiencies.
    Aiuti F; Businco L; Fiorilli M; Galli E; Quinti I; Rossi P; Seminara R; Goldstein G
    Lancet; 1983 Mar; 1(8324):551-4. PubMed ID: 6131256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Normalization of the CD4/CD8 lymphocyte ratio and increased B lymphocytes in long standing diabetic patients following therapy with thymopentin.
    Pozzilli P; Visalli N; Cavallo MG; Beales P; Negri M; Ghirlanda G; Papa V; Andreani D
    Diabetes Res; 1987 Oct; 6(2):51-6. PubMed ID: 2962799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thymopentin in the treatment of alopecia areata.
    Orecchia G
    Dermatologica; 1989; 178(4):231. PubMed ID: 2670621
    [No Abstract]   [Full Text] [Related]  

  • 24. [Use of thymopentin in the therapy of recurrent oral ulcers].
    Robotti MP; Fabbri G; Baldin C; Faccioli G; Ciaffoni S
    Minerva Stomatol; 1988 Jun; 37(6):497-503. PubMed ID: 3050443
    [No Abstract]   [Full Text] [Related]  

  • 25. [Use of thymopentin in the treatment of post-radiation cystitis].
    Martinoli F; Catania G; Bertana F; Caldera G
    Minerva Urol Nefrol; 1988; 40(4):275-6. PubMed ID: 3075095
    [No Abstract]   [Full Text] [Related]  

  • 26. An immunomodulating drug, thymopentin, in the treatment of progressive systemic sclerosis.
    Giordano N; Biasi G; Taddeo A; Marcolongo R; Bertelletti D
    Clin Rheumatol; 1989 Jun; 8(2):293-4. PubMed ID: 2667863
    [No Abstract]   [Full Text] [Related]  

  • 27. Thymopentin administration and increase of sero-conversion after B-hepatitis vaccine in diabetic patients.
    Pagani S; Cruciani L; Chianelli M; Procaccini E; Pozzilli P
    Diabetes Res; 1989 Dec; 12(4):199-201. PubMed ID: 2534655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Possible selective effects of thymopentin on polymorphonuclear activity in patients undergoing dialysis].
    Salvati F
    Recenti Prog Med; 1989 Sep; 80(9):499. PubMed ID: 2687987
    [No Abstract]   [Full Text] [Related]  

  • 29. Immunomodulation in infection caused by human immunodeficiency virus.
    Phair JP
    J Lab Clin Med; 1989 Feb; 113(2):135-6. PubMed ID: 2644386
    [No Abstract]   [Full Text] [Related]  

  • 30. Thymopoietin pentapeptide (TP-5) improves clinical parameters and lymphocyte subpopulations in atopic dermatitis.
    Kang K; Cooper KD; Hanifin JM
    J Am Acad Dermatol; 1983 Mar; 8(3):372-7. PubMed ID: 6339571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FcIgG receptor-bearing lymphocytes and monoclonal antibody-defined T cell subsets in atopic dermatitis: effect of treatment with thymopoietin pentapeptide (TP-5).
    Strannegård O; Strannegård IL; Kang K; Cooper KD; Hanifin JM
    Int Arch Allergy Appl Immunol; 1982; 69(3):238-44. PubMed ID: 6752042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of marrow graft recipients with thymopentin.
    Witherspoon RP; Navari R; Storb R; Sullivan KM; Doney K; Beatty P; Lum LG; Thomas ED
    Bone Marrow Transplant; 1987 Apr; 1(4):365-71. PubMed ID: 3332144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement of natural killer activity and of T cells after thymopoietin pentapeptide therapy in a patient with severe combined immunodeficiency.
    Fiorilli M; Sirianni MC; Pandolfi F; Quinti I; Tosti U; Aiuti F; Goldstein G
    Clin Exp Immunol; 1981 Aug; 45(2):344-51. PubMed ID: 7032772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale for thymopentin as therapeutic agent in rheumatoid arthritis.
    Franchimont P; Bolla K
    Surv Immunol Res; 1985; 4 Suppl 1():70-5. PubMed ID: 3898295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of the TP5 analogue of thymopoietin on the rejection of male skin by aged and thymectomized female mice.
    Goldberg EH; Goldstein G; Boyse EA; Scheid MP
    Immunogenetics; 1981; 13(3):201-4. PubMed ID: 7024116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Thymopentin and immune response in patients with cancer].
    Petronella P; Ferrone R; Freda F; Valeriani G
    Minerva Chir; 1989 Sep; 44(18):2017-20. PubMed ID: 2694011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of cutaneous T-cell lymphomas with TP-5. Evaluation of the clinical effect in 8 patients.
    Przybilla B; Burg G; Schmoeckel C; Braun-Falco O
    Acta Derm Venereol; 1983; 63(6):524-9. PubMed ID: 6198843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thymopoietin pentapeptide (thymopentin, TP-5) in the treatment of rheumatoid arthritis. A compilation of several short- and longterm clinical studies.
    Veys EM; Mielants H; Verbruggen G; Spiro T; Newdeck E; Power D; Goldstein G
    J Rheumatol; 1984 Aug; 11(4):462-6. PubMed ID: 6384507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thymopentin (TP-5) in the treatment of the postburn and postoperative immunodeficiency syndrome.
    Hamilton G; Zöch G; Rath T; Meissl G
    Prog Clin Biol Res; 1989; 308():995-9. PubMed ID: 2528748
    [No Abstract]   [Full Text] [Related]  

  • 40. [A case of juvenile rheumatoid arthritis treated with thymopentin].
    Tucciarone L; Felici W; Greco L; Mechelli A
    Minerva Pediatr; 1989 Feb; 41(2):109-11. PubMed ID: 2661988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.